48 Search Results


Search Again

Fred Appelbaum , MD

Email: fappelba@fredhutch.org

Phone: 206-667-4412

Dr. Appelbaum’s research focuses on the biology and treatment of leukemias, lymphomas and other blood cancers. He was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.

View Bio

Alice Berger , PhD

Email: ahberger@fredhutch.org

Phone: (206) 667-6281

The goal of the Berger laboratory is to enable precision medicine by systematically uncovering the molecular alterations in cancer, determining the function of these variant alleles, and understanding how these alleles modulate response to targeted or immune-based therapies. Although many of the genes involved in cancer have now been identified, a major challenge is discovering which specific alleles of these genes are involved and how these alleles modulate therapeutic response. We combine functional genomics, computational biology, biochemistry, and genetics to understand the mechanism of somatic cancer variants. Our goal is to identify drug targets and biomarkers and to translate this knowledge into clinical benefit for patients.

View Bio

Ryan Cassaday , MD

Email: cassaday@uw.edu

Phone: (206) 288-1202

Dr. Cassaday is interested in testing novel treatments and developing improved risk-stratification methods for adults with acute lymphoblastic leukemia. In addition, he is studying radioimmunotherapy-based conditioning regimens for stem cell transplantation as treatment for adults with high-risk lymphoma.

View Bio

Aude Chapuis , MD

Email: achapuis@fredhutch.org

Phone: (206) 667-4369

Dr. Chapuis’ translational research laboratory is developing novel ways to modulate the immune system to target cancer. Her research is especially focused on 1) understanding the factors associated with successful “adoptive” transfer of immune T cells and improving the therapeutic efficacy of both natural (native) and gene-modified T cells targeting viral and tumor antigens, and 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T cells so as to better eliminate tumor targets. These advances are in turn used to 3) develop clinical strategies to optimally activate therapeutic T cells to specifically eliminate cancer in patients, without the noxious side effects of chemotherapy.

View Bio

Thomas Chauncey , MD

Email: tchaunce@u.washington.edu

Dr. Chauncey is a medical oncologist who treats leukemia with bone marrow transplantation.

View Bio

Eric Chow , MD, MPH

Email: ericchow@uw.edu

Phone: (206) 667-7724

Dr. Chow studies late effects related to pediatric cancer and blood disorder therapy.

View Bio

Victor Chow , MD

Email: vchow@fredhutch.org

Phone: (206) 667-7731

Dr. Chow conducts clinical research in lymphoma utilizing combination approaches with cellular-based therapies.

View Bio

Bruce Clurman , MD, PhD

Email: bclurman@fredhutch.org

Phone: (206) 667-4524

Dr. Clurman's studies the pathways that regulate cell growth and division in order to understand the molecular mechanisms that drive tumorigenesis and to develop new cancer therapies. His research focuses on two general areas: cellular regulation by the ubiquitin-proteasome system, and control of cell division by cyclin-dependent kinases (CDKs).His clinical practice is focused on hematopoietic stem cell transplantation.

View Bio

Andrew Cowan , MD

Email: ajcowan@fredhutch.org

Phone: (206) 667-7348

Dr. Cowan specializes in indolent lymphomas, multiple myeloma, and AL amyloidosis and is involved in clinical trials in lymphomas.

View Bio

David Fredricks , MD

Email: dfredric@fredhutch.org

Phone: (206) 667-1935

Dr. Fredricks's lab has identified several fastidious bacterial species that are useful markers of BV and are associated with adverse health outcomes. They are using novel cultivation methods to propagate some of these bacteria in the lab, and study how indigenous microbes interact with each other and the human host. He is currently looking for collaboration in molecular biology, microbiology, immunology, and cell biology. He is also looking for collaborators to focus on clinical epidemiology by studying microbial ecology in different human hosts.

View Bio

Jordan Gauthier , MD, MSc

Email: jgauthier@fredhutch.org

Phone: (206) 667-2713

Much of Dr. Gauthier's research has been focused on improving outcomes for patients treated with BMT or CAR T-cell therapy. Through his work, he has identified factors that can help predict the success of CAR T-cell therapy for patients who have leukemia and lymphoma.

View Bio

Ted Gooley , PhD

Email: tgooley@fredhutch.org

Phone: (206) 667-6533

Dr. Gooley's research is focused on clinical trials and methods of data analysis in stem cell transplantation.

View Bio

Ajay Gopal , MD

Email: agopal@u.washington.edu

Dr. Gopal specializes in the treatment of lymphoma, chronic lymphocytic leukemia and novel low toxicity therapies.His reseach is focused on developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity Proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.

View Bio

Damian Green , MD

Email: dgreen@fredhutch.org

Phone: (206) 667-5398

Dr. Green’s laboratory and clinical research is focused on developing new immunotherapeutic approaches to treat and ultimately eradicate multiple myeloma and lymphoma.

View Bio

Marshall Horwitz , MD, PhD

Email: horwitz@uw.edu

Phone: (206) 616-4566

Dr. Marshall Horwitz is an internist and clinical medical geneticist whose research interests relate to genetic factors predisposing to hematopoietic malignancy and the clonal evolution of cancer. The major focus of his research centers on defining the genetic origins of cancers of the blood and using that as a paradigm for further understanding development. His laboratory employs genetic mapping and sequencing strategies to identify genes responsible for familial predisposition to leukemia, lymphoma, and bone marrow failure syndromes. In related work, Dr. Horwitz's laboratory has developed a new approach for mapping cell fate during development by inferring the order in which mutations accumulate in somatic tissues.

View Bio

Billanna Hwang , MPH, DHSc

Email: bhwang@uw.edu

Dr. Hwang’s research focuses include development of immunotherapies in lung and VCA transplants, tolerance and acute/chronic rejection immunology (Tregs), pathophysiology of GVHD, NSCLC, and exosome biology (therapies, biomarker). Most recently, her group has expanded using cell and exosome based immunotherapies in Cystic Fibrosis and role of bioengineered materials to promote regeneration through exo-mechanisms.

View Bio

Teresa Hyun , MD, PhD

Email: thyun@fredhutch.org

Phone: (206) 606-1345

Dr. Hyun is a pathologist who works in hematopathology and bone marrow transplant pathology. Her clinical work involves evaluation of hematolymphoid malignancies which may require treatment with bone marrow/stem cell transplantation and monitoring of post-transplant conditions such as graft-versus-host disease as part of the clinical team treating patients at SCCA.

View Bio

Brian Iritani , DVM, PhD

Email: biritani@u.washington.edu

Phone: (206) 221-3932

Dr. Iritani's lab is studying the Myc oncogene family, Myc proteins are deregulated in many types of cancers including breast, brain, colon cancers, and most leukemias and lymphomas. He is interested in understanding how these proteins normally function in the development and proliferation of lymphocytes, and how these functions are altered during oncogenic activation. Utilizing cDNA microarray technology, his lab has identified sets of genes that are regulated by Myc in primary lymphocytes both before and after transformation.

View Bio

Elizabeth Krakow , MD

Email: efkrakow@fredhutch.org

Phone: (206) 667-3410

Dr. Krakow is interested in using HLA-mismatched non-engrafting cell therapy to treat cancer. The goal is to avoid graft-versus-host disease and long-term immunosuppression, but still harness transient benefits of direct alloreactivity while restoring the recipient (or original donor) immune system’s cancer surveillance and eradication mechanisms. She also studies how to deliver personalized recommendations for sequences of chemo/immunotherapies.

View Bio